Jacob Lalezari REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JACOB LALEZARI, Quest Clinical Research, San Francisco Maraviroc could be a
Jacob Lalezari
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007JACOB LALEZARI, Quest Clinical Research, San FranciscoMaraviroc could be a useful new drug for the treatment of some HIV infections, according toJacob Lalezariof Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
Related Episodes
Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JUAN BERENGUER, Hospital Gregorio Marañón, Madrid A ret
Broad Approach, Including Computer System, to Improve Hospital Hygiene
Yehuda Carmeli REFERENCE: Abstract K-1373, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 YEHUDA CARMELI, Tel-Aviv Medical Center Hospitals can pre
DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
Pedro Cahn REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires Etraviri